Palatin Technologies, Inc.

As of February 13, 2025, Palatin Technologies, Inc. has deteriorated to a "does not qualify" valuation grade due to negative financial ratios and a year-to-date return of -84.68%, indicating it is overvalued and not a viable investment compared to its peers and the S&P 500.

As of February 13, 2025, Palatin Technologies, Inc. is considered overvalued and has moved from a risky to a "does not qualify" valuation grade due to significant financial concerns, including negative valuation metrics and a year-to-date stock return of -86.49%.

As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages and KST signals, despite some mild bullishness in the MACD, with overall indicators showing uncertainty and lack of strong bullish momentum.

As of March 2022, the management team of Palatin Technologies, Inc. includes Dr. John Prendergast (Independent Chairman), Dr. Carl Spana (President and CEO), and several Independent Directors: Mr. Robert deVeer, Dr. Alan Dunton, Mr. Joseph Hull, Dr. Anthony Manning, and Ms. Arlene Morris. They oversee the company's strategic direction and governance.

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted therapeutics that affect the melanocortin and natriuretic peptide receptor systems. It operates as a micro-cap company with a market cap of $5.25 million and reported a net profit loss of $5 million as of March 2025.

As of June 18, Palatin Technologies, Inc. has a market capitalization of 5.25 million, categorizing it as a Micro Cap company, with net sales of 0.35 million and a net profit of -23.32 million for the latest four quarters. As of June 2024, shareholder's funds were -0.11 million, and total assets were 10.74 million.